GPCR-Targeting Therapies Market Poised for Strong Growth During the Forecast Period (2025-2034) Across 7MM Due to the Rising Cancer Diagnoses and Drug Pipeline Expansion
LAS VEGAS, June 30, 2025 /PRNewswire/ — DelveInsight's GPCR-Targeting Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as PTCL, CTCL, migraine, NASH, and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging GPCR-targeting therapies, market share of individual therapies, and current and forecasted GPCR-targeting therapies market size from 2020 to 2034, segmented into 7MM.
Key Takeaways from the GPCR-Targeting Therapies Market Report
As per DelveInsight's analysis, the total market size of GPCR-targeting therapies in the 7MM is expected to surge significantly by 2034.
The United States is expected to hold the largest share of the total GPCR inhibitors market among the 7MM.
The report provides the total potential number of patients in the indications, such as PTCL, CTCL, Migraine, NASH, and others.
Leading GPCR-targeting therapies companies, such as CytoDyn, REMD Biotherapeutics, GPCR Therapeutics, Structure Therapeutics, and others, are developing novel GPCR-targeting therapies that can be available in the GPCR-targeting therapies market in the coming years.
Some of the key GPCR-targeting therapies in the pipeline include Leronlimab, Volagidemab, GPC-100, GSBR-1290, and others.
In July 2024, Radionetics Oncology entered into a strategic agreement with Eli Lilly and Company, providing Lilly access to Radionetics' proprietary GPCR targeting small molecule radiopharmaceuticals.
Discover which indication is expected to grab the major GPCR-targeting therapies market share @ GPCR-Targeting Therapies Market Report
GPCR-Targeting Therapies Market Dynamics
The GPCR-targeting therapies market is experiencing dynamic growth, driven by advances in drug discovery technologies, an expanding understanding of GPCR biology, and the therapeutic relevance of these receptors in a wide array of diseases. GPCRs represent the largest family of membrane receptors in humans and are involved in regulating various physiological processes, making them attractive targets for drug development. Approximately 30–40% of currently approved drugs act on GPCRs, underscoring their clinical and commercial significance.
One of the key market dynamics is the diversification of therapeutic areas beyond traditional indications such as cardiovascular diseases and neurological disorders. Recent research has highlighted the role of GPCRs in oncology, metabolic disorders, and immune-mediated diseases, fueling interest in developing novel ligands, biased agonists, and allosteric modulators that offer greater specificity and reduced side effects. The development of precision medicine approaches and better structural characterization of GPCRs using cryo-electron microscopy have further enabled the design of highly targeted therapies.
Pharmaceutical companies are increasingly investing in GPCR-focused pipelines, often in collaboration with biotechnology firms and academic research institutions. Strategic partnerships, licensing deals, and acquisitions are common, aiming to access novel chemistries and platform technologies, such as structure-based drug design, high-throughput screening, and artificial intelligence-enabled ligand discovery. These collaborations are vital for accelerating R&D timelines and reducing attrition rates in clinical development.
However, the market also faces several challenges, including the inherent complexity of GPCR signaling pathways, the risk of off-target effects, and the difficulty of achieving functional selectivity. Regulatory hurdles, high development costs, and the need for robust biomarkers for patient stratification further complicate commercialization efforts. Despite these barriers, the pipeline remains robust, with a growing number of GPCR-targeting candidates advancing through preclinical and clinical stages.
Overall, the GPCR-targeting therapies market is poised for sustained expansion, supported by scientific innovation, a growing demand for targeted treatments, and the therapeutic versatility of GPCRs. With the convergence of computational biology, structural pharmacology, and translational research, the next wave of GPCR-targeting drugs is expected to offer novel mechanisms of action and improved patient outcomes across diverse indications.
GPCR-Targeting Therapies Treatment Market
The market outlook for GPCR-targeting therapies is promising, driven by successful drugs like ZAVZPRET, POTELIGEO, AIMOVIG, and VYEPTI. ZAVZPRET is an innovative small-molecule antagonist of the CGRP receptor, approved for the acute treatment of migraines, both with and without aura, in adults. It works by inhibiting the CGRP receptor, which plays a key role in migraine development by contributing to neurogenic inflammation and blood vessel dilation. Administered as a nasal spray, ZAVZPRET allows for quick absorption through the nasal lining, providing direct access to the bloodstream while bypassing the digestive system and first-pass liver metabolism.
POTELIGEO, developed by Kyowa Kirin, is a humanized monoclonal antibody that targets the CCR4 receptor—a protein commonly found on certain cancerous T-cells. By binding to CCR4, the drug helps recruit immune cells to attack and eliminate malignant cells, thereby boosting the body's immune defense against cancer. Initially approved in Japan in 2012 for relapsed or refractory CCR4-positive adult T-cell leukemia (ATL), its indication was expanded in 2014 to include relapsed or refractory CCR4-positive peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). The U.S. FDA approved POTELIGEO in 2018 for Mycosis Fungoides and Sézary Syndrome, with similar approvals granted in Europe. In June 2020, the drug became commercially available in Germany for adults with Mycosis Fungoides or Sézary Syndrome who had undergone at least one prior systemic treatment.
Erenumab, co-developed by Amgen and Novartis, is a fully human monoclonal antibody that selectively binds to and blocks CGRP receptors. CGRP ligands, which are small neuropeptides, contribute to migraine and chronic pain through strong vasodilatory effects. By directly competing with CGRP, erenumab provides a high degree of specificity and effectiveness compared to small-molecule therapies. It is used to treat conditions such as migraine, vasoconstriction, hot flashes, and stable angina pectoris. The antibody received approval in the U.S. in May 2018 and in the EU in July 2018.
Learn more about the FDA-approved GPCR-targeting therapies @ GPCR-Targeting Therapies Drugs
Key Emerging GPCR-Targeting Therapies and Companies
Several key players, including CytoDyn (Leronlimab), REMD Biotherapeutics (Volagidemab), Structure Therapeutics (GSBR-1290), GPCR Therapeutics (GPC-100), and others, are involved in developing drugs for GPCR-targeting therapies for various indications such as NASH, Multiple Myeloma, Diabetes, and others.
Volagidemab (REMD-477) is a human monoclonal antibody targeting the glucagon receptor (GCGR), developed by REMD Biotherapeutics for the treatment of juvenile type I diabetes (T1D) and type II diabetes (T2D). It functions by binding to GCGR and competitively inhibiting its signaling pathway. This action enhances glucose uptake by the liver, reduces the breakdown of glycogen and gluconeogenesis, and stimulates glycogen synthesis—collectively contributing to its blood sugar-lowering effects (CK060182). As of March 2021, the drug was being investigated in multiple indications: T1D and T2D were in Phase II clinical trials, glucose intolerance was in Phase I, and metabolic disorders were in the preclinical stage (CK060183).
Leronlimab is classified as a viral entry inhibitor, a type of HIV therapy that blocks the virus from penetrating and infecting healthy cells. In contrast to Highly Active Antiretroviral Therapy (HAART), which targets HIV after cell entry and replication, Leronlimab intervenes earlier in the viral life cycle. The critical role of the CCR5 receptor in HIV infection is highlighted by the natural immunity observed in individuals with a genetic mutation that disables CCR5 expression. Leronlimab is currently under development for the treatment of Nonalcoholic Steatohepatitis (NASH), HIV-associated NASH, and various solid tumors, with development efforts currently in Phase II.
In April 2019, the company signed multiple agreements with Samsung for the transfer of technology, process validation, manufacturing, and pre-approval inspection services, aimed at supporting the commercial production of Leronlimab's bulk drug substance.
The anticipated launch of these emerging therapies are poised to transform the GPCR-targeting therapies market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the GPCR-targeting therapies market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about GPCR-targeting therapies clinical trials, visit @ GPCR-Targeting Therapies Treatment Drugs
GPCR-Targeting Therapies Overview
G protein-coupled receptors (GPCRs) are a vital group of cell surface receptors that regulate numerous physiological processes. In many cancers, GPCR pathways are often dysregulated due to abnormal expression, increased activity, or mutations, contributing to uncontrolled cell growth, blood vessel formation, and metastasis. GPCRs are categorized into several classes based on their structure and function. In humans, the primary classes include Class A (Rhodopsin-like), Class B (Secretin and Adhesion), Class C (Metabotropic glutamate/pheromone), and Class F (Frizzled/TAS2).
Additional classes, such as Class D (fungal mating pheromone receptors) and Class E (cyclic AMP receptors), are present in non-human organisms. Among these, Class A is the most extensive, encompassing a majority of hormone, neurotransmitter, and sensory receptors. Class B is split into secretin and adhesion subgroups, Class C comprises receptors for glutamate and GABA, and Class F includes receptors like frizzled and smoothened involved in Wnt signaling. This classification underscores the structural and functional diversity of GPCRs and their critical roles in both normal physiology and disease.
GPCR-Targeting Therapies Epidemiology Segmentation
The GPCR-targeting therapies market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into:
Total Cases in Selected Indications for GPCR-Targeting Therapies
Total Eligible Patient Pool in Selected Indications for GPCR-Targeting Therapies
Total Treated Cases in Selected Indications for GPCR-Targeting Therapies
GPCR-Targeting Therapies Report Metrics
Details
Study Period
2020–2034
GPCR-Targeting Therapies Report Coverage
7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Key Indications Covered in the Report
PTCL, CTCL, Migraine, NASH, and others
Key GPCR-Targeting Therapies Companies
CytoDyn, REMD Biotherapeutics, GPCR Therapeutics, Structure Therapeutics, Pfizer, Kyowa Hakko Kirin, Novartis, Amgen, Lundbeck, and others
Key GPCR-Targeting Therapies
Leronlimab, Volagidemab, GPC-100, GSBR-1290, ZAVZPRET, POTELIGEO, AIMOVIG, VYEPTI, and others
Scope of the GPCR-Targeting Therapies Market Report
GPCR-Targeting Therapies Therapeutic Assessment: GPCR-Targeting Therapies current marketed and emerging therapies
GPCR-Targeting Therapies Market Dynamics: Conjoint Analysis of Emerging GPCR-Targeting Therapies Drugs
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL's views, Analyst's views, GPCR-Targeting Therapies Market Access and Reimbursement
Discover more about GPCR-targeting therapies in development @ GPCR-Targeting Therapies Clinical Trials
Table of Contents
1.
Key Insights
2.
Report Introduction
3.
Executive Summary
4.
Key Events
5.
Epidemiology and Market Forecast Methodology
6.
GPCR-Targeting Therapies Market Overview at a Glance in the 7MM
6.1.
Market Share (%) Distribution by Indications in 2020
6.2.
Market Share (%) Distribution by Indications in 2034
7.
GPCR-Targeting Therapies: Background and Overview
7.1.
Introduction
7.2.
Potential of GPCR-Targeting Therapies in Different Indications
7.3.
Clinical Applications of GPCR-Targeting Therapies
8.
Treatment and Management
9.
Target Patient Pool of GPCR-Targeting Therapies
9.1.
Assumptions and Rationale
9.2.
Key Findings
9.3.
Total Cases of Selected Indication for GPCR-Targeting Therapies in the 7MM
9.4.
Total Eligible Patient Pool of Selected Indication for GPCR-Targeting Therapies in the 7MM
9.5.
Total Treatable Cases in Selected Indication for GPCR-Targeting Therapies in the 7MM
10.
Marketed Therapies
10.1.
Key Competitors
10.2.
OTELIGEO (mogamulizumab-kpkc): Kyowa Hakko Kirin
10.2.1.
Product Description
10.2.2.
Regulatory milestones
10.2.3.
Other developmental activities
10.2.4.
Clinical development
10.2.5.
Safety and efficacy
10.3.
AIMOVIG (erenumab-aooe): Novartis/Amgen
10.3.1.
Product Description
10.3.2.
Regulatory milestones
10.3.3.
Other developmental activities
10.3.4.
Clinical development
10.3.5.
Safety and efficacy
List to be continued in the report
11.
Emerging Therapies
11.1.
Key Competitors
11.2.
Volagidemab: REMD Biotherapeutics
11.2.1.
Product Description
11.2.2.
Other developmental activities
11.2.3.
Clinical development
11.2.4.
Safety and efficacy
11.3.
Leronlimab: CytoDyn
11.3.1.
Product Description
11.3.2.
Other developmental activities
11.3.3.
Clinical development
11.3.4.
Safety and efficacy
12.
GPCR-Targeting Therapies: Seven Major Market Analysis
12.1.
Key Findings
12.2.
Market Outlook
12.3.
Conjoint Analysis
12.4.
Key Market Forecast Assumptions
12.4.1.
Cost Assumptions and Rebates
12.4.2.
Pricing Trends
12.4.3.
Analogue Assessment
12.4.4.
Launch Year and Therapy Uptakes
12.5.
Total Market Sizes of GPCR-Targeting Therapies by Indications in the 7MM
12.6.
The United States Market Size
12.6.1.
Market Size by Indication in the United States
12.6.2.
Market Size by Therapies in the United States
12.7.
EU4 and the UK
12.7.1.
Market Size by Indications in EU4 and the UK
12.7.2.
Market Size by Therapies in EU4 and the UK
12.8.
Japan
12.8.1.
Market Size by Indications in Japan
12.8.2.
Market Size by Therapies in Japan
13.
KOL Views
14.
Unmet Needs
15.
Market Access and Reimbursement
16.
Appendix
16.1.
Bibliography
16.2.
Report Methodology
17.
DelveInsight Capabilities
18.
Disclaimer
19.
About DelveInsight
Related Reports
Migraine Market
Migraine Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key migraine companies, including Lundbeck Seattle BioPharmaceutical, Eli Lilly and Company, Amgen, Novartis, Teva Pharmaceuticals, Allergan, Biohaven Pharmaceuticals, Dr. Reddy's Labs, AbbVie, Impel NeuroPharma, Zosano Pharma, Axsome Therapeutics, Aeon Biopharma Inc., Ionis Pharmaceuticals, Inc., Charleston Laboratories, among others.
Metabolic Dysfunction-Associated Steatohepatitis Market
Metabolic Dysfunction-Associated Steatohepatitis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key MASH companies, including Inventiva Pharma, Novo Nordisk A/S, Cirius Therapeutics, Inc., Akero Therapeutics, Inc., 89bio, Inc., Boehringer Ingelheim, Zealand Pharma, Galectin Therapeutics Inc., Lipocine Inc., Viking Therapeutics, Inc., Eli Lilly and Company, Boston Pharmaceuticals, Pfizer, HighTide Biopharma, CytoDyn, Inc., Merck & Co., Hanmi Pharmaceutical, Hepagene (Shanghai) Co., Ltd., Hepion Pharmaceuticals, Inc., Enyo Pharmaceuticals, Gilead Sciences, Poxel SA, Zydus Therapeutics, Sagimet Biosciences Inc., Ionis Pharmaceuticals, Corcept Therapeutics, among others.
Cutaneous T-Cell Lymphoma Market
Cutaneous T-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CTCL companies, including Pfizer, Helsinn Therapeutics, Kyowa Hakko Kirin, Citius Pharmaceuticals, Soligenix, Prescient Therapeutics, Innate Pharma, Bristol-Myers Squibb, BioInvent International AB, among others.
Peripheral T-Cell Lymphoma Market
Peripheral T-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PTCL companies, including Secura Bio, Shanghai YingLi Pharmaceutical, Dizal Pharmaceuticals, Viracta Therapeutics, Innate Pharma, CStone Pharmaceuticals, Affimed, Otsuka Pharmaceutical, Astex Pharmaceuticals, Autolus, Myeloid Therapeutics, Merck Sharp & Dohme, Bristol Myers Squibb, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur info@delveinsight.com +14699457679
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/gpcr-targeting-therapies-market-poised-for-strong-growth-during-the-forecast-period-20252034-across-7mm-due-to-the-rising-cancer-diagnoses-and-drug-pipeline-expansion–delveinsight-302494131.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
2 hours ago
- Malaysian Reserve
Zuowei Technology Shining at WHX Miami Medical Expo
SHENZHEN, China, July 1, 2025 /PRNewswire/ — From June 11 to 13, the 2025 WHX Miami Medical Expo (formerly known as FIME), the annual grand event of the medical industry in the Americas, was held at the Miami Beach Convention Center. As one of the largest and most influential professional exhibitions for medical devices and equipment in the Americas, WHX Miami attracted top companies from around the world, serving as a vital hub connecting the healthcare markets of North America, South America, and the Caribbean. Among the many exhibitors, Shenzhen Zuowei Technology Co., Ltd. from China stood out with its impressive presence. Its cutting-edge intelligent nursing robots and innovative solutions became a highlight of the expo, drawing significant attention from attendees and industry professionals alike. Zuowei Technology showcased a series of its latest Intelligent Incontinence Cleaning product at the expo, including Gait Training Electric Wheelchair, Portable Bed Shower Machine, and Foldable Electric Mobility Scooter. Among them, the Portable Bed Shower Machine stood out with its compact design and powerful functionality. Specially developed for individuals with limited mobility, this device breaks through the traditional constraints of bathing environments and labor demands. With its one-touch intelligent operation, constant temperature system, and safety-focused design, the machine makes the bathing process easy, safe, and convenient. The Gait Training Electric Wheelchair also garnered significant attention at the expo. Equipped with high-precision sensors and an intelligent navigation system, it provides stable and secure walking assistance for individuals with mobility impairments. Meanwhile, the foldable electric mobility scooter, known for its 'small size, big power,' features a lightweight, easily foldable design for effortless transport, extended battery life, and a comfortable riding experience—bringing newfound freedom of movement to users facing travel limitations. These products seamlessly integrate cutting-edge technologies such as artificial intelligence (AI) and the Internet of Things (IoT) into caregiving scenarios. They not only highlight Zuowei Technology's strong R&D capabilities in intelligent nursing solutions but also reflect the keen insight of Chinese enterprises into the evolving global care market. During the three-day exhibition, the Zuowei Technology team welcomed over 100 clients from around the world with great enthusiasm and professionalism. Among them were long-term overseas partners who have worked closely with the company for years, as well as new clients who were instantly drawn to the unique appeal of Zuowei's products upon first contact. A U.S.-based distributor shared his thoughts with the media: 'Zuowei's products are truly outstanding. I believe there will be strong demand for them in the U.S. market. We look forward to establishing a long-term partnership with Zuowei Technology to jointly promote the development of intelligent caregiving technologies.' The company's representative, in an interview with reporters, commented: 'This exhibition holds great significance for us. We see it as a key opportunity to accelerate our international expansion, actively explore global markets, and provide high-quality, efficient products and solutions to clients worldwide.' In recent years, as Chinese enterprises continue to achieve breakthroughs in core technologies and demonstrate remarkable product innovation, an increasing number of Chinese medical technology products are gaining recognition in international markets. Zuowei Technology has already established stable business relationships with partners in over 50 countries and regions worldwide, earning widespread praise and trust. Dedicated to intelligent care for the disabled elderly, Zuowei Technology focuses on six essential caregiving needs—toileting, bathing, eating, getting in and out of bed, walking, and dressing. The company provides comprehensive solutions combining intelligent nursing series and smart caregiving platforms, delivering more thoughtful, professional, and technology-driven elderly care experiences to users around the globe. Zuowei remains committed to contributing to the global senior care industry with cutting-edge innovation and heartfelt service.
Malaysian Reserve
3 hours ago
- Malaysian Reserve
Halozyme Therapeutics Added to Russell 1000® Index
SAN DIEGO, June 30, 2025 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that it has been added to the U.S. large-cap Russell 1000® Index, effective after market close on June 27th, as part of the 2025 FTSE Russell indexes annual reconstitution. The Russell 1000® Index includes approximately 1,000 of the largest U.S. securities based on market capitalization and is widely used by investors as a benchmark for the performance of large-cap stocks. 'Joining the Russell 1000 Index is an important milestone that reflects our leadership in rapid large-volume subcutaneous drug delivery and our track record of durable top-and-bottom line growth,' said Dr. Helen Torley, President and CEO of Halozyme. 'The inclusion will help to expand our visibility among the investment community as we continue to execute our strategy and deliver sustainable growth and profitability well into the future.' The Russell 1000® is managed by FTSE Russell, a global leader in index and analytics. Membership in the Russell 1000® Index, which remains in place for one year, is based on membership in the broad-market Russell 3000® Index. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products in at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals. Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc. Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility. For more information visit and connect with us on LinkedIn and Twitter. Safe Harbor Statement In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning the future execution of Halozyme's strategy and delivery of future sustainable growth and profitability, the durability of Halozyme's top and bottom line growth, the possible activity, benefits and attributes of ENHANZE®, the possible method of action of ENHANZE®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs, and statements concerning certain other potential benefits of ENHANZE® including facilitating more rapid delivery of injectable medications through subcutaneous delivery and potentially lowering the treatment burden for patients. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words 'expect,' 'believe,' 'enable,' 'may,' 'will,' 'could,' 'intends,' 'estimate,' 'anticipate,' 'plan,' 'predict,' 'probable,' 'potential,' 'possible,' 'should,' 'continue,' and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected results in the execution of Halozyme's strategy and unexpected future financial results and top and bottom line growth,. These and other factors that may result in differences are discussed in greater detail in Halozyme's most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission. Except as required by law, Halozyme undertakes no duty to update forward-looking statements to reflect events after the date of this release. Contacts: Tram BuiVP, Investor Relations and Corporate Communications609-333-7668tbui@ Sydney
Malaysian Reserve
7 hours ago
- Malaysian Reserve
EPAM Recognized as Top IT Service Vendor in UK & Ireland for Second Year in a Row
Ranked number 1 by clients in the UK&I for financial services and technology innovation, EPAM has established itself as a leading IT service provider across overall customer satisfaction, account management, service delivery and application services NEWTOWN, Pa., July 1, 2025 /PRNewswire/ — With organizations under pressure to drive growth, reduce operational costs and mitigate digital risk, many senior IT decision makers are partnering with specialist IT vendors to onboard AI transformation safely, adopt advanced computing practices and enhance human-machine collaboration. EPAM Systems, Inc. (NYSE: EPAM), a leading digital transformation services and product engineering company, today announced it has been named a Top IT Vendor in the UK and Ireland (UK&I), achieving high customer satisfaction performance rankings across various evaluation criteria by Whitelane Research, an independent organization focused on IT sourcing research across Europe. 'We're honored to be recognized by our clients as a top IT services partner in the UK and Ireland, including securing the number one ranking in financial services and technology innovation,' said Ben Brinkworth, VP, Account Management at EPAM. 'As we evolve into an AI-powered transformation company, we remain focused on helping our clients accelerate their own AI journeys by applying best-in-class AI technologies across the full software development lifecycle, and combining them with our deep engineering expertise, strategic advisory and product delivery capabilities to create measurable value and business outcomes for our clients.' In the 2025 UK&I IT Sourcing Study by Whitelane Research, nearly 400 respondents from the top IT spending organizations evaluated more than 1000 unique IT sourcing relationships based on key performance indicators and by IT domain. Survey respondents evaluated 38 IT service providers across various performance categories, delivering one of the most comprehensive voice-of-the-customer reports on the IT vendor market in the region. In this evaluation, EPAM earned top-tier satisfaction rankings in the following categories: Technology & Service Innovation: EPAM ranked #1 Financial Services: EPAM ranked #1, receiving a rating of 85% General Satisfaction: EPAM received a rating of 83% Account Management Quality: EPAM received a rating of 83% Service Delivery Quality: EPAM received a rating of 83% Application Services: EPAM received a rating of 83% 'In this year's UK&I IT Sourcing Study, EPAM earned high customer-satisfaction rankings across multiple evaluation criteria, particularly cementing its position as an innovation leader in the region,' said Alex Van Den Bergh, Head of Research, Europe at Whitelane Research. 'Surveyed clients consistently highlighted EPAM's deep technical proficiency, exceptional account management and relationship building, agile resource deployment and a partnership-driven operating model that aligns effectively with their strategic priorities.' Recognized throughout Europe by Whitelane Research and clients for commendable customer satisfaction, EPAM helps clients in scaling and transforming across various industries through its technical capabilities across digital, AI, data, cloud and engineering. With more than 1,900 professionals across the UK and Ireland, and regional offices in London, Newcastle, Manchester, Belfast, Dublin and Newry, EPAM delivers leading-edge digital transformation, product design and engineering services tailored to the evolving needs of clients throughout the region. Recent customer-led recognitions by Whitelane Research have underscored EPAM's performance as a highly competitive IT partner to organizations across various European markets: Top IT Vendor in the Nordics, April 2025 Top IT Vendor in the Netherlands, March 2025 Top IT Vendor in Europe, February 2025 Top IT Vendor in Germany, November 2024 Top IT Vendor in Switzerland, September 2024 To see the full survey results, visit: About EPAM SystemsSince 1993, EPAM Systems, Inc. has used its software engineering expertise to become a leading global provider of digital engineering, cloud and AI-enabled transformation services, and a leading business and experience consulting partner for global enterprises and ambitious startups. We address our clients' transformation challenges by focusing EPAM Continuum's integrated strategy, experience and technology consulting with our 30+ years of engineering execution to speed our clients' time to market and drive greater value from their innovations and digital investments. We leverage AI and GenAI to deliver transformative solutions that accelerate our clients' digital innovation and enhance their competitive edge. Through platforms like EPAM AI/RUN™ and initiatives like DIALX Lab, we integrate advanced AI technologies into tailored business strategies, driving significant industry impact and fostering continuous innovation. We deliver globally but engage locally with our expert teams of consultants, architects, designers and engineers, making the future real for our clients, our partners, and our people around the world. We believe the right solutions are the ones that improve people's lives and fuel competitive advantage for our clients across diverse industries. Our thinking comes to life in the experiences, products and platforms we design and bring to market. Added to the S&P 500 and the Forbes Global 2000 in 2021 and recognized by Glassdoor and Newsweek as Most Loved Workplace, our multidisciplinary teams serve customers across six continents. We are proud to be among the top 15 companies in Information Technology Services in the Fortune 1000 and to be recognized as a leader in the IDC MarketScapes for Worldwide Experience Build Services, Worldwide Experience Design Services and Worldwide Software Engineering Services. Learn more at and follow us on LinkedIn. Photo – Logo – View original content:
